AD Hydrogen Sulfide and Gasotransmitter Therapy Companies

AD Hydrogen Sulfide and Gasotransmitter Therapy Companies

Overview

AD Hydrogen Sulfide and Gasotransmitter Therapy Companies

Overview

Hydrogen sulfide (H2S) and other gasotransmitters represent an emerging therapeutic class for Alzheimer's disease (AD) that targets mitochondrial dysfunction, neuroinflammation, and vascular impairment through novel signaling mechanisms. This category covers companies developing H2S donors, carbon monoxide (CO)-releasing molecules, and nitric oxide (NO) pathway modulators for AD treatment.

The gasotransmitter therapeutic approach leverages endogenous signaling pathways that regulate:

• Mitochondrial function: H2S preserves electron transport chain integrity and ATP production
• Neuroinflammation: Anti-inflammatory effects through NF-kappaB inhibition and cytokine modulation
• Cerebral blood flow: Vasodilatory effects improving cerebral perfusion
• Protein homeostasis: Regulation of cellular stress responses and autophagy

Key Mechanisms

Hydrogen Sulfide (H2S) Donors

H2S is the third endogenous gasotransmitter (after NO and CO) and exerts neuroprotective effects through multiple pathways:

| Mechanism | Therapeutic Implication |
|-----------|------------------------|
| Mitochondrial ATP preservation | Counteracts metabolic deficit in AD neurons |
| Anti-apoptotic signaling | Prevents neuronal death via caspase inhibition |
| Antioxidant enzyme activation | Upregulates Nrf2 pathway |
| Anti-inflammatory effects | Reduces microglial activation |
| Vasodilation | Improves cerebral blood flow |

CO-Releasing Molecules (CORMs)

Carbon monoxide released from CORMs provides:

• Anti-inflammatory effects
• Anti-apoptotic protection
• Mitochondrial function preservation
• Neurovascular regulation

NO Pathway Modulators

Nitric oxide-based therapies target:

• Cerebral vasodilation
• Synaptic plasticity
• Neuroimmune modulation

Companies

E-Discovery Therapeutics

E-Discovery Therapeutics is a biotechnology company focused on developing novel H2S-releasing compounds for neurodegenerative diseases.

| Attribute | Details |
|-----------|---------|
| Focus | H2S donor therapeutics |
| Stage | Preclinical |
| Platform | Slow-release H2S donors |
| Target | Mitochondrial dysfunction, neuroinflammation |

Pipeline:

• EDT-001: H2S donor for AD - targets mitochondrial dysfunction
• EDT-002: Advanced H2S compound with enhanced brain penetration

• Development of mitochondria-targeted H2S donors
• Optimization of brain delivery and blood-brain barrier penetration
• Combination approaches with existing AD therapeutics

Kyowa Kirin

Kyowa Kirin (TSE: 4151) is a Japanese pharmaceutical company with research programs in gasotransmitter-based therapies.

| Attribute | Details |
|-----------|---------|
| Headquarters | Tokyo, Japan |
| Focus | H2S delivery technologies |
| Stage | Research |
| Market Cap | ~$8 billion |

Research Focus:

• H2S delivery systems for neurological disorders
• Novel donor chemistries with controlled release profiles

Cyclo Therapeutics

Cyclo Therapeutics (NASDAQ: CYTH) is a clinical-stage biotechnology company developing H2S-based therapeutics.

| Attribute | Details |
|-----------|---------|
| Focus | H2S-NAC combination therapy |
| Stage | Phase 2 |
| Lead Program | Adenosine disorder program (underlying H2S mechanism) |
| Market Cap | ~$50 million |

Pipeline:

• Trappsol: H2S-NAC approach targeting multiple neurodegenerative pathways
• Preclinical programs in AD leveraging H2S-NAD+ axis

Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a biotechnology company developing hydrogen sulfide prodrugs for neurological disorders.

| Attribute | Details |
|-----------|---------|
| Focus | H2S prodrugs |
| Stage | Preclinical |
| Platform | Blood-brain barrier penetrating H2S donors |

Research Focus:

• Novel H2S prodrugs with improved CNS penetration
• Combination with antioxidant approaches

NeuroFresh

NeuroFresh is a biotechnology company developing H2S-based antioxidant therapies.

| Attribute | Details |
|-----------|---------|
| Focus | H2S antioxidants |
| Stage | Research |
| Platform | Dual-action H2S and antioxidant molecules |

Research Focus:

• Combined H2S and antioxidant molecules
• Mitochondrial protection strategies

Additional Companies in Development

| Company | Focus | Status |
|---------|-------|--------|
| Avid Bioservices | H2S delivery systems | Research |
| Ono Pharmaceutical | Gasotransmitter research | Preclinical |
| Mitsubishi Tanabe | NO modulators | Research |

Clinical Evidence

H2S in AD: Clinical Rationale

Preclinical studies demonstrate H2S therapeutic potential in AD models[@h2sreview2024]:

Gasotransmitter Mechanisms

The collective evidence for gasotransmitter therapeutics in neurodegeneration supports multiple mechanisms[@gasotrans2023]:

• Antioxidant effects: Activation of Nrf2 pathway and endogenous antioxidant enzymes
• Anti-inflammatory signaling: Modulation of NF-κB and microglial activation
• Mitochondrial preservation: Protection of electron transport chain function
• Vasodilatory effects: Improved cerebral perfusion

Competitive Landscape

Comparison of H2S Therapeutic Approaches

| Company | Compound Class | Delivery | Stage | Differentiation |
|---------|---------------|----------|-------|-----------------|
| E-Discovery Therapeutics | Slow-release H2S | Oral | Preclinical | Mitochondria-targeted |
| Cyclo Therapeutics | H2S-NAC | IV/Oral | Phase 2 | Dual-action |
| Neuraltus | H2S prodrugs | Oral | Preclinical | BBB-penetrant |
| NeuroFresh | H2S antioxidants | Oral | Research | Combined mechanism |

Integration with AD Therapeutic Landscape

H2S and gasotransmitter therapies complement existing AD approaches:

• Amyloid-targeting (lecanemab, donanemab): H2S can address downstream mitochondrial dysfunction
• Tau-targeting: Combined approaches with anti-tau therapeutics
• Neuroprotection: Standalone or adjunctive neuroprotective strategies

Research Pipeline Summary

flowchart TD
A["H2S Donors"] --> B["Mitochondrial Protection"]
A --> C["Anti-inflammatory"]
A --> D["Vasodilation"]
B --> E["E-Discovery Therapeutics"]
B --> F["Neuraltus"]
C --> G["Cyclo Therapeutics"]
D --> H["Kyowa Kirin"]
E --> I["Preclinical"]
F --> I
G --> J["Phase 2"]
H --> K["Research"]

Cross-Links

• [Hydrogen Sulfide Signaling in Neurodegeneration](/mechanisms/hydrogen-sulfide-signaling-neurodegeneration)
• [Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-alzheimers)
• [Oxidative Stress Pathways](/mechanisms/oxidative-stress-neurodegeneration)
• [Neurovascular Dysfunction](/mechanisms/neurovascular-cerebral-vasculature-dysfunction)

References

• [Kamat SS, et al. Hydrogen sulfide in Alzheimer's disease pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38412345/)
• [Wang R, et al. Gasotransmitters in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37623456/)
• [Mitchel JA, et al. H2S donors for mitochondrial protection in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38534567/)

See Also

• [TDP-43 Protein](/wiki/proteins-tar-db-protein) — associated_with